Cambridge, UK; September 29, 2016. Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI) disorders, announces that is a finalist in the 12th Annual pharmaceutical industry Scrip Awards. The awards programme is organised by Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry.

The nomination in the category of “Financing Deal of the Year” comes on the back of Atlantic Healthcare closing the $24m financing round in March 2016. Not only did the fundraise provide the investment required to take Atlantic Healthcare’s first product through to ‘market ready’, but also attracted world-leading experience in the GI sector. Lorin Johnson, who joined the company as an investor and board member, was a founder of Salix Pharmaceuticals, the world’s largest GI specialty pharma by revenues before it’s $15.8bn acquisition by Valeant Pharmaceuticals (NYSE:VRX). The funds have enabled the Group to intiate a Phase 3 trial of alicaforsen enema to treat pouchitis, establish commercial teams in business development and sales & marketing, plus strengthen the management team.

According to Scrip, “In making their decision, the judges scrutinised entrants on their fundraising strategy, amount raised, the structure of the deal, and on how the money would be used.” The judges also assessed additional success criteria from the fundraising, such as “bringing on board a new kind of investor.”

Toby Wilson Waterworth, CEO at Atlantic Healthcare said: “We’re delighted to be a finalist for this prestigious Scrip Award. Since submission for the award, earlier in the year, we have continued to progress our pivotal Phase 3 alicaforsen trial in pouchitis, our story will have progressed again before the awards ceremony in November, when we look forward to hearing the winners.”

 

For more information please contact:

Atlantic Healthcare
Toby Wilson Waterworth (CEO)
+44 1799 513 391

Adam Michael (Head of Communications)

+44 1799 512 055
+44 777 588 1813

adam.michael@atlantichc.com

European Investor Relations and Media
Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal

+44 20 3709 5700

atlantichealthcare@consilium-comms.com

 

Notes to Editors:

About Atlantic Healthcare plc (www.atlantichc.com)

Atlantic Healthcare is an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal disorders including Inflammatory Bowel Disease (IBD). The Group’s lead product is alicaforsen enema, in a pivotal Phase 3 trial for pouchitis, and in preparation for Phase 3 clinical development in ulcerative colitis (UC).

Alicaforsen is also generating early repeat revenues in Europe through unsolicited requests via the Named Patient Supply protocols. The Group has FDA and EMA orphan drug designations, and an FDA letter of fast-track, for alicaforsen in pouchitis. Atlantic Healthcare has a highly committed investor base, and an experienced international leadership team. Atlantic Healthcare’s fundraising to date includes £1.9m through SBRI funding with InnovateUK, the UK Government’s innovation agency (www.innovateuk.gov.uk). In Q1 2016 the Group closed a $24m round led by LDC (the private equity division of Lloyd’s Banking Group), with investment from founders of both Salix Pharmaceuticals and Clinigen Group, and existing shareholders.

About Alicaforsen

Alicaforsen enema has the potential to establish a new class of therapy for the treatment of inflammatory bowel disease (IBD), with clear differentiating features.
Alicaforsen enema is currently in a Phase 3 trial agreed with U.S., Canadian and European regulatory agencies in patients with active, chronic pouchitis. The trial is recruiting 138 patients to approximately 40 trial centres across the U.S., Canada, and Europe. Alicaforsen is an antisense oligonucleotide with a novel mode of action for treatment of IBD. Alicaforsen targets ICAM-1, a cell-surface protein which is involved in the inflammatory response and is over-expressed in patients with IBD.

Alicaforsen enema is being developed as a locally active topical formulation which has demonstrated, in five Phase 2 clinical studies involving 377 patients, an ability to reduce inflammation and promote mucosal healing with good tolerability and a durable effect. Alicaforsen enema has commenced Phase 3 for pouchitis and is ready to commence Phase 3 for active distal ulcerative colitis (UC). There is currently no approved treatment for pouchitis in the U.S. or Europe and there are limited treatment options for UC.

Alicaforsen in pouchitis has an FDA letter of fast track plus U.S. and European orphan drug designations. Alicaforsen is generating early repeat revenues in Europe through unsolicited requests via the Named Patient Supply protocols. This has demonstrated further evidence of efficacy and safety in the pouchitis[1] and UC indications [2,3] .

References:
Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. Thomas Greuter, Luc Biedermann, Gerhard Rogler, Bernhard Sauter and Frank Seibold. UEG Journal (2015) DOI: 10.1177/2050640615593681 Alicaforsen Retention Enema Induces Long-Term Remission in Patients with Ulcerative Colitis. Zaid Heetun, David Gibson, Denise Keegan, Kathryn Byrne, Hugh E Mulcahy, Garret Cullen, Glen A Doherty. Irish Soc Gastroenterol Nov 2014 Alicaforsen, ICAM-1 enema as a treatment option when treating distal ulcerative colitis . LA. Bark 1 , I. Löfberg 1 , B. Håkansson 1 , U. Sjöqvist 1 (www.atlantichc.com/la-bark-abstract-pdf)